297 related articles for article (PubMed ID: 35931041)
1. Assessment of Objective and Subjective Cognitive Function in Patients With Treatment-Resistant Depression Undergoing Repeated Ketamine Infusions.
Phillips JL; Van Geel A; Burhunduli P; Vasudev D; Batten LA; Norris S; Talbot J; Ortiz A; Owoeye O; Blier P
Int J Neuropsychopharmacol; 2022 Dec; 25(12):992-1002. PubMed ID: 35931041
[TBL] [Abstract][Full Text] [Related]
2. Single, Repeated, and Maintenance Ketamine Infusions for Treatment-Resistant Depression: A Randomized Controlled Trial.
Phillips JL; Norris S; Talbot J; Birmingham M; Hatchard T; Ortiz A; Owoeye O; Batten LA; Blier P
Am J Psychiatry; 2019 May; 176(5):401-409. PubMed ID: 30922101
[TBL] [Abstract][Full Text] [Related]
3. Efficacy, Safety, and Durability of Repeated Ketamine Infusions for Comorbid Posttraumatic Stress Disorder and Treatment-Resistant Depression.
Albott CS; Lim KO; Forbes MK; Erbes C; Tye SJ; Grabowski JG; Thuras P; Batres-Y-Carr TM; Wels J; Shiroma PR
J Clin Psychiatry; 2018; 79(3):. PubMed ID: 29727073
[TBL] [Abstract][Full Text] [Related]
4. Neurocognitive effects of six ketamine infusions and the association with antidepressant response in patients with unipolar and bipolar depression.
Zhou Y; Zheng W; Liu W; Wang C; Zhan Y; Li H; Chen L; Li M; Ning Y
J Psychopharmacol; 2018 Oct; 32(10):1118-1126. PubMed ID: 30260273
[TBL] [Abstract][Full Text] [Related]
5. Single and repeated ketamine infusions for reduction of suicidal ideation in treatment-resistant depression.
Phillips JL; Norris S; Talbot J; Hatchard T; Ortiz A; Birmingham M; Owoeye O; Batten LA; Blier P
Neuropsychopharmacology; 2020 Mar; 45(4):606-612. PubMed ID: 31759333
[TBL] [Abstract][Full Text] [Related]
6. Clinical outcomes in the biomarkers of ketamine (Bio-K) study of open-label IV ketamine for refractory depression.
Parikh SV; Vande Voort JL; Yocum AK; Achtyes E; Goes FS; Nykamp L; Singh B; Lopez-Vives D; Sera CE; Maixner D; Tarnal V; Severe J; Bartek S; Tye SJ; Rico J; Stoppel CJ; Becerra A; Smart L; Miller CR; Frye MA; Greden JF; Bobo WV
J Affect Disord; 2024 Mar; 348():143-151. PubMed ID: 38142892
[TBL] [Abstract][Full Text] [Related]
7. Neurocognitive performance of repeated versus single intravenous subanesthetic ketamine in treatment resistant depression.
Shiroma PR; Thuras P; Wels J; Albott CS; Erbes C; Tye S; Lim KO
J Affect Disord; 2020 Dec; 277():470-477. PubMed ID: 32871534
[TBL] [Abstract][Full Text] [Related]
8. A comparative analysis of antidepressant and anti-suicidal effects of repeated ketamine infusions in elderly and younger adults with depression.
Zheng W; Zhou YL; Wang CY; Lan XF; Ning YP
J Affect Disord; 2023 Aug; 334():145-151. PubMed ID: 37160235
[TBL] [Abstract][Full Text] [Related]
9. Electrophysiological correlates and predictors of the antidepressant response to repeated ketamine infusions in treatment-resistant depression.
de la Salle S; Phillips JL; Blier P; Knott V
Prog Neuropsychopharmacol Biol Psychiatry; 2022 Apr; 115():110507. PubMed ID: 34971723
[TBL] [Abstract][Full Text] [Related]
10. Neurocognitive effects of subanesthetic serial ketamine infusions in treatment resistant depression.
Zavaliangos-Petropulu A; McClintock SM; Khalil J; Joshi SH; Taraku B; Al-Sharif NB; Espinoza RT; Narr KL
J Affect Disord; 2023 Jul; 333():161-171. PubMed ID: 37060953
[TBL] [Abstract][Full Text] [Related]
11. The effectiveness of repeated intravenous ketamine on subjective and objective psychosocial function in patients with treatment-resistant depression and suicidal ideation.
Zhou Y; Wang C; Lan X; Zheng W; Li H; Chao Z; McIntyre RS; Ning Y
J Affect Disord; 2022 May; 304():78-84. PubMed ID: 35176337
[TBL] [Abstract][Full Text] [Related]
12. The potential pro-cognitive effects with intravenous subanesthetic ketamine in adults with treatment-resistant major depressive or bipolar disorders and suicidality.
Zhou Y; Wang C; Lan X; Zheng W; Li H; Chao Z; Wu K; McIntyre RS; Ning Y
J Psychiatr Res; 2021 Dec; 144():312-319. PubMed ID: 34715598
[TBL] [Abstract][Full Text] [Related]
13. Anxiety during ketamine infusions is associated with negative treatment responses in major depressive disorder.
Aust S; Gärtner M; Basso L; Otte C; Wingenfeld K; Chae WR; Heuser-Collier I; Regen F; Cosma NC; van Hall F; Grimm S; Bajbouj M
Eur Neuropsychopharmacol; 2019 Apr; 29(4):529-538. PubMed ID: 30772118
[TBL] [Abstract][Full Text] [Related]
14. Rapid and longer-term antidepressant effects of repeated-dose intravenous ketamine for patients with unipolar and bipolar depression.
Zheng W; Zhou YL; Liu WJ; Wang CY; Zhan YN; Li HQ; Chen LJ; Li MD; Ning YP
J Psychiatr Res; 2018 Nov; 106():61-68. PubMed ID: 30278319
[TBL] [Abstract][Full Text] [Related]
15. Neurocognitive effects of repeated ketamine infusion treatments in patients with treatment resistant depression: a retrospective chart review.
Dai D; Miller C; Valdivia V; Boyle B; Bolton P; Li S; Seiner S; Meisner R
BMC Psychiatry; 2022 Feb; 22(1):140. PubMed ID: 35193541
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of Intravenous Ketamine in Adolescent Treatment-Resistant Depression: A Randomized Midazolam-Controlled Trial.
Dwyer JB; Landeros-Weisenberger A; Johnson JA; Londono Tobon A; Flores JM; Nasir M; Couloures K; Sanacora G; Bloch MH
Am J Psychiatry; 2021 Apr; 178(4):352-362. PubMed ID: 33653121
[TBL] [Abstract][Full Text] [Related]
17. A randomized, double-blind, active placebo-controlled study of efficacy, safety, and durability of repeated vs single subanesthetic ketamine for treatment-resistant depression.
Shiroma PR; Thuras P; Wels J; Albott CS; Erbes C; Tye S; Lim KO
Transl Psychiatry; 2020 Jun; 10(1):206. PubMed ID: 32591498
[TBL] [Abstract][Full Text] [Related]
18. Repeated subcutaneous racemic ketamine in treatment-resistant depression: case series.
Tham JCW; Do A; Fridfinnson J; Rafizadeh R; Siu JTP; Budd GP; Lam RW
Int Clin Psychopharmacol; 2022 Sep; 37(5):206-214. PubMed ID: 35695279
[TBL] [Abstract][Full Text] [Related]
19. Change in neurocognitive functioning in patients with treatment-resistant depression with serial intravenous ketamine infusions: The Bio-K multicenter trial.
Singh B; Parikh SV; Voort JLV; Pazdernik VK; Achtyes ED; Goes FS; Yocum AK; Nykamp L; Becerra A; Smart L; Greden JF; Bobo WV; Frye MA; Burdick KE; Ryan KA
Psychiatry Res; 2024 May; 335():115829. PubMed ID: 38479192
[TBL] [Abstract][Full Text] [Related]
20. Ketamine vs Electroconvulsive Therapy for Treatment-Resistant Depression: A Secondary Analysis of a Randomized Clinical Trial.
Jha MK; Wilkinson ST; Krishnan K; Collins KA; Sanacora G; Murrough J; Goes F; Altinay M; Aloysi A; Asghar-Ali A; Barnett B; Chang L; Costi S; Malone D; Nikayin S; Nissen SE; Ostroff R; Reti I; Wolski K; Wang D; Hu B; Mathew SJ; Anand A
JAMA Netw Open; 2024 Jun; 7(6):e2417786. PubMed ID: 38916891
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
